EUVIMEDEUVIMED entdecken
Crossref

Reframing the immunotherapy landscape in borderline resectable pancreatic ductal adenocarcinoma: progress or plateau?

Alice Cattelani, Isabella Frigerio

AME Clinical Trials Review · 2026-04 · 4 · 18-18

DOI: 10.21037/actr-25-101 ↗

Kurz gefasst

Fachartikel in der Zeitschrift AME Clinical Trials Review, 2026-04. Verfasst von Alice Cattelani und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Cattelani, A., & Frigerio, I. (2026). Reframing the immunotherapy landscape in borderline resectable pancreatic ductal adenocarcinoma: progress or plateau?. AME Clinical Trials Review, 4, 18-18. https://doi.org/10.21037/actr-25-101

Vancouver

Cattelani A, Frigerio I. Reframing the immunotherapy landscape in borderline resectable pancreatic ductal adenocarcinoma: progress or plateau?. AME Clinical Trials Review. 2026;4:18-18. doi:10.21037/actr-25-101

BibTeX
@article{Cattelani2026,
  author = {Cattelani, Alice and Frigerio, Isabella},
  title = {Reframing the immunotherapy landscape in borderline resectable pancreatic ductal adenocarcinoma: progress or plateau?},
  journal = {AME Clinical Trials Review},
  year = {2026},
  volume = {4},
  pages = {18--18},
  doi = {10.21037/actr-25-101}
}
Kostenlos starten →